Filtered By:
Drug: Herceptin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 51 results found since Jan 2013.

Inhibiting HER3 Hyperphosphorylation in HER2 ‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells
A multimodal theranostic nanoplatform to treat breast cancer overexpressing the human epidermal growth factor receptors 2 (HER2) and 3 (HER3) is developed, and consisting of doxorubicin-loaded branched gold nanoshells functionalized with a small interfering RNA against HER3 and the HER2-specific antibody Trastuzumab able to simultaneously combine chemo- and photothermal, RNA silencing and immuno-therapies overcoming chemoresistance and reducing tumor size in vivo. AbstractTreatment failure in breast cancers overexpressing human epidermal growth factor receptor 2 (HER2) is associated mainly to the upregulation of human epid...
Source: Small - August 26, 2023 Category: Nanotechnology Authors: Eva Villar ‐Alvarez, Irene Golán‐Cancela, Alberto Pardo, Brenda Velasco, Javier Fernández‐Vega, Adriana Cambón, Abeer Al‐Modlej, Antonio Topete, Silvia Barbosa, José A. Costoya, Pablo Taboada Tags: Research Article Source Type: research

Precision Therapy  of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot
Schematic illustration of the preparation of a HER2/CD44-targeted hydrogel nanobot (ALPR) by embedding the positively charged bio-responsive, liposome-encapsulated nanoparticles (LPR) formed by cationic liposome DOTAP/DOPE, survivin siRNA, andD-(KLAKLAK)2GGR16 (KLA-R16) into negatively charged Herceptin/hyaluronic acid cross-linked nanohydrogels (Herceptin-HA). AbstractHeterogeneity and drug resistance of tumor cells are the leading causes of incurability and poor survival for patients with recurrent breast cancer. In order to accurately deliver the biological anticancer drugs to different subtypes of malignant tumor cells...
Source: Small - May 8, 2023 Category: Nanotechnology Authors: Juan Chen, Jinjin Li, Xiaolu Sun, Huixia Lu, Kuai Liu, Zhenbo Li, Jianyue Guan, Huiling Song, Wei Wei, Yanhong Ge, Qiong Fan, Wei Bao, Buyong Ma, Zixiu Du Tags: Research Article Source Type: research

PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
We examined three HER2-positive, ER-negative breast cancer cell lines to determine the efficacy of a novel alpha isoform-specific PI3K inhibitor in combination with trastuzumab. The results indicated that this combination was effective in PIK3CA-mutant or PTEN-deficient breast cancer cells by inducing apoptosis and inhibiting the expression of downstream proteins. PTEN loss by siRNA modulation in parental HER2-positive cancer cells with PI3K signaling pathway alterations could not confer resistance to alpelisib or GDC-0077 plus trastuzumab. We selected the CK-MB-1 cell line without alterations in the PI3K pathway to demons...
Source: Cell Research - August 15, 2022 Category: Cytology Authors: Wei-Pang Chung Wei-Lun Huang Chun-Hui Lee Hui-Ping Hsu Wan-Ling Huang You-Yu Liu Wu-Chou Su Source Type: research

Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis
This research paper describes a new therapeutic candidate based on a nanoparticle that co-delivers siRNA against human epidermal growth factor receptor type 2 (HER2), trastuzumab, and docetaxel to treat advanced HER2+ breast cancer. The nanotherapeutic is more effective and safer than the free drug counterparts. It inhibits drug-resistant orthotopic and brain-metastatic HER2+ breast tumors in mice. AbstractThe first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or pacli...
Source: Small - January 27, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz ‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee Tags: Research Article Source Type: research

Characterization of T ‐DM1‐resistant breast cancer cells
AbstractThe development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T ‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trastuzumab and the microtubule cytotoxic agent DM1 (emtansine). Despite clinical successes achieved by targeted therapies, a large number of patients develop resistance during treatment. To explore mechanisms of resistance to T‐DM1, the MDA‐MB‐361 HER2‐positive breast cancer cell line was exposed in vitro to T‐DM1 ...
Source: Pharmacology Research and Perspectives - June 23, 2020 Category: Drugs & Pharmacology Authors: Juliette Sauveur, Louise Conilh, Sabine Beaumel, Kamel Chettab, Lars ‐Petter Jordheim, Eva‐Laure Matera, Charles Dumontet Tags: ORIGINAL ARTICLE Source Type: research

319PThe role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach
ConclusionsOur results suggest: 1) RCL were more proliferative, more mesenchymal-like and stem cell-like properties; 2) AXL was a potential mechanism of secondary resistance to T; 3) Combination therapy with AXL inhibitor plus T restored sensitivity in in vitro model with AXL overexpression; 4) AXL expression was associated with relapse in HER2+ BC patients. These results showed AXL as a prognostic factor and a potential therapeutic target in HER2+ patients with resistance to T.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureA. Lluch: Advisory / Consultancy: Novartis; Advisor...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells
In conclusion, an efficient liposomal delivery system for the combination of miRNA and siRNA to target the BCSCs was developed and could be used as an efficacious therapeutic modality for breast cancer.Graphical AbstractHerceptin-conjugated cationic liposome can enhance the cellular uptake of let-7 miRNA and CDK4 siRNA toward the HER-2 expressing breast cancer stem cells.
Source: Asian Journal of Pharmaceutical Sciences - May 8, 2019 Category: Drugs & Pharmacology Source Type: research

Gene Therapy Leaves a Vicious Cycle
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research

Non-canonical Notch Signaling Regulates Actin Remodeling in Cell Migration by Activating PI3K/AKT/Cdc42 Pathway
In conclusion, our research results indicate that DAPT activates PI3K/AKT/Cdc42 signaling by non-canonical Notch pathway, and the activated Cdc42 promotes the filopodia formation and inhibits lamellipodia assembly, resulting in reduced migration of breast cancer cells. The results imply that non-canonical Notch signaling may play a very important role in the rapid response of cells to the extracellular signals. Author Contributions LG, JD, and LL designed the study and wrote and revised the manuscript. LL and LZ performed most of the experiments and data analysis. SZ, X-YZ, P-XM, Y-DM, Y-YW, YC, S-JT, and Y-JZ assisted i...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
In conclusion, osmotic burst of inflated complement-damaged cells may occur, but these bursts are most likely a consequence of metabolic collapse of the cell rather than the cause of cell death. The Complement Cell Death Mediator: A Concerted Action of Toxic Moieties Membrane pores caused by complement were first visualized by electron microscopy on red blood cell membranes as large ring structures (22). Similar lesions were viewed on E. coli cell walls (23). Over the years, ample information on the fine ultrastructure of the MAC that can activate cell death has been gathered (24) and has been recently further examined (...
Source: Frontiers in Immunology - April 9, 2019 Category: Allergy & Immunology Source Type: research

MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer.
Conclusions: Our results firstly indentified that high levels of MEOX1 especially nuclear staining was an independent prognostic factor for NSCLC, and it served a essential roles in the regulation of cell proliferation and colony formation in vitro. It may represent a potential target for the NSCLC treatment. PMID: 30662330 [PubMed - in process]
Source: International Journal of Medical Sciences - January 22, 2019 Category: Biomedical Science Tags: Int J Med Sci Source Type: research

HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in a NF κB-dependent way.
In this study, we explored the effect of HER2 on cancer stem cells induction and drug sensitivity of ovarian cancer cell lines. Firstly, we found that HER2 overexpression (HER2 OE) induced, while HER2 knockdown (HER2 KD) decreased CD44+/CD24- population. Consistently, HER2 expression was closely correlated with the sphere formation efficiency (SFE) of ovarian cancer cells. Secondly, we found that NFκB inhibition by specific inhibitor JSH23 or siRNA targeting subunit p65 dramatically impaired the induction of ovarian cancer stem cells by HER2, indicating that NFκB mediated HER2-induced ovarian cancer stem cells. Thirdly, ...
Source: Bioscience Reports - October 12, 2018 Category: Biomedical Science Authors: Wang W, Gao Y, Hai J, Yang J, Duan S Tags: Biosci Rep Source Type: research